Independence Health System has introduced Memory Clinics offering new therapies for early Alzheimer’s disease. Lecanemab and soon Donanemab are provided to patients at Excela Health and Butler Health System campuses. These drugs have been approved by the FDA and target amyloid-beta plaques associated with Alzheimer’s. While some praise them as breakthrough therapies, controversy surrounds their safety and effectiveness. Some studies suggest only minimal benefits and potential risks, including brain swelling and bleeding. Despite this, IHS remains focused on providing hope to patients and their loved ones, acknowledging the cost-benefit decision involved in using these medications.
Source link
New medications for early Alzheimer’s draw praise, controversy
